Bioxcel Therapeutics Equity-NMS: BTAI

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$20.94

52W high :

$34.13

1Y :

80.02%

5Y :

93.96%

Shares O/S :

29.16 M

Market cap :

589.02 M

What is the share price of Bioxcel Therapeutics today?

Bioxcel Therapeutics (BTAI) share price as of June 7, 2023, is $20.94. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Bioxcel Therapeutics?

Yes, Indian Investors can invest in the Bioxcel Therapeutics (BTAI) Share by opening an international trading account with Angel One.

How can I purchase Bioxcel Therapeutics shares in India?

Purchasing Bioxcel Therapeutics (BTAI) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Bioxcel Therapeutics (BTAI) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Bioxcel Therapeutics?

Yes, you can purchase fractional shares of Bioxcel Therapeutics (BTAI) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Bioxcel Therapeutics?

The market capitalization of Bioxcel Therapeutics on June 7, 2023, is $592.96 M.

In which sector Bioxcel Therapeutics belongs?

Bioxcel Therapeutics operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Bioxcel Therapeutics stocks?

In order to invest in Bioxcel Therapeutics (BTAI) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.